EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Daniel H Palmer, Richard Jackson, Christoph Springfeld iD, Paula Ghaneh, Charlotte Rawcliffe, Christopher M Halloran iD, Olusola Faluyi iD, David Cunningham iD, Jonathan Wadsley iD, Suzanne Darby, Tim Meyer iD, Roopinder Gillmore und 21 weitere

Journal of Clinical Oncology · 05.12.2024

DOI: 10.1200/jco.24.01118 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, online erschienen am 05.12.2024. Verfasst von Daniel H Palmer und 32 weiteren Autor:innen. Beteiligte Einrichtung: University of Liverpool, Liverpool, United Kingdom. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) than gemcitabine but had more restrictive eligibility criteria. Our aim was to analyze the ESPAC4 survival on long-term follow-up. METHODS The OS of 732 ESPAC4 patients comparing 367 randomly assigned to gemcitabine and 365 to GemCap was previously reported after a median follow-up time of 43.2 months (95% CI, 39.7 to 45.5) and 458 deaths. Analysis was now carried out after a median follow-up of 104 months (101-108) and 566 deaths. RESULTS The median OS was 29.5 months (27.5-32.1) for all patients, 28.4 months (25.2-32.0) in the gemcitabine group and 31.6 months (26.5-38.0) in the GemCap group (hazard ratio [HR], 0.83 [0.71 to 0.98]; P = .031). R0 patients given gemcitabine had a median survival of 32.2 months (27.9-41.6) compared with 49.9 months (39.0-82.3) for those given GemCap (HR, 0.63 [0.47 to 0.84]; P = .002). Lymph node-negative patients had significantly higher 5 year OS rates on GemCap (59% [49%-71%]) than gemcitabine (53% [42%-66%]; HR, 0.63 [0.41 to 0.98]; P = .04) but not those with positive lymph nodes ( P = .225). The OS advantage for GemCap was retained in the PRODIGE24 subgroup of 193 (26.4%) ESPAC4 patients not eligible for PRODIGE24 with a median survival of 20.7 (16.2-27.3) months in patients allocated to gemcitabine compared with 25.9 (22.3-30.2) months for ineligible patients allocated to GemCap (HR, 0.71 [95% CI, 0.52 to 0.98]; χ 2 log-rank-1df = 4.31; P = .038). CONCLUSION GemCap is a standard option for patients not eligible for mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious in R0 patients and also in lymph node-negative patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsAdenocarcinomaHumansDeoxycytidineGemcitabineFemaleMaleMiddle AgedChemotherapy, AdjuvantAgedCapecitabineFluorouracilAdultLeucovorinTreatment OutcomeIrinotecanOxaliplatinOrganoplatinum Compounds

Substanzen

DeoxycytidineGemcitabineCapecitabineFluorouracilLeucovorinIrinotecanOxaliplatinOrganoplatinum Compounds

Autor:innen und Institutionen

  • University of Liverpool, Liverpool, United Kingdom.
  • Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Champalimaud Foundation, Lisbon, Portugal.
  • The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom.
  • Royal Marsden Hospital, London, United Kingdom.
  • Weston Park Cancer Centre, Sheffield, United Kingdom.

ORCID-Profile: Christoph Springfeld, Christopher M Halloran, Olusola Faluyi, David Cunningham, Jonathan Wadsley, Tim Meyer, Yuk Ting Ma, Sebastian Cummins, Paul J Ross, Harpreet Wasan, David Borg, Juan W Valle, Christoph Michalski, John P Neoptolemos

Zitieren

APA

Palmer, D. H., Jackson, R., Springfeld, C., Ghaneh, P., Rawcliffe, C., Halloran, C. M., Faluyi, O., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Lind, P., Glimelius, B., Falk, S., Ma, Y. T., Middleton, G. W., Cummins, S., Ross, P. J., …, & Neoptolemos, J. P. (2024). Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.01118

Vancouver

Palmer DH, Jackson R, Springfeld C, Ghaneh P, Rawcliffe C, Halloran CM, et al. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.01118

BibTeX
@article{Palmer2024,
  author = {Palmer, Daniel H and Jackson, Richard and Springfeld, Christoph and Ghaneh, Paula and Rawcliffe, Charlotte and Halloran, Christopher M and Faluyi, Olusola and Cunningham, David and Wadsley, Jonathan and Darby, Suzanne and Meyer, Tim and Gillmore, Roopinder and Lind, Pehr and Glimelius, Bengt and Falk, Stephen and Ma, Yuk Ting and Middleton, Gary William and Cummins, Sebastian and Ross, Paul J and Wasan, Harpreet and McDonald, Alec and Crosby, Tom and Hammel, Pascal and Borg, David and Sothi, Sharmila and Valle, Juan W and Mehrabi, Arianeb and Bailey, Peter and Tjaden, Christine and Michalski, Christoph and Hackert, Thilo and Büchler, Markus W and Neoptolemos, John P},
  title = {Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.01118}
}
Kostenlos starten →